# Michael T Heneka

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 242 papers | 33,439 citations | 4388 86 h-index | 4228 174 g-index |
| 260 all docs | 260 docs citations | 260 times ranked | 35613 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Neuroinflammation in Alzheimer's disease. Lancet Neurology, The, 2015, 14, 388-405. | 10.2 | 4,129 |
| 2 | NLRP3 is activated in Alzheimerâ€™s disease and contributes to pathology in APP/PS1 mice. Nature, 2013, 493, 674-678. | 27.8 | 2,063 |
| 3 | Innate immune activation in neurodegenerative disease. Nature Reviews Immunology, 2014, 14, 463-477. | 22.7 | 1,053 |
| 4 | NLRP3 inflammasome activation drives tau pathology. Nature, 2019, 575, 669-673. | 27.8 | 782 |
| 5 | New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436. | 21.4 | 700 |
| 6 | Inflammatory processes in Alzheimer's disease. Journal of Neuroimmunology, 2007, 184, 69-91. | 2.3 | 664 |
| 7 | Microglia-derived ASC specks cross-seed amyloid-Î² in Alzheimerâ€™s disease. Nature, 2017, 552, 355-361. | 27.8 | 664 |
| 8 | Microglia in Alzheimerâ€™s disease. Journal of Clinical Investigation, 2017, 127, 3240-3249. | 8.2 | 622 |
| 9 | Innate immunity in Alzheimer's disease. Nature Immunology, 2015, 16, 229-236. | 14.5 | 619 |
| 10 | TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science Translational Medicine, 2014, 6, 243ra86. | 12.4 | 600 |
| 11 | Acute treatment with the PPARÎ³ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1â€“42 levels in APPV717I transgenic mice. Brain, 2005, 128, 1442-1453. | 7.6 | 522 |
| 12 | Inflammasome signalling in brain function and neurodegenerative disease. Nature Reviews Neuroscience, 2018, 19, 610-621. | 10.2 | 514 |
| 13 | A guiding map for inflammation. Nature Immunology, 2017, 18, 826-831. | 14.5 | 506 |
| 14 | Glial cells in (patho)physiology. Journal of Neurochemistry, 2012, 121, 4-27. | 3.9 | 460 |
| 15 | Antineoplastic effects of peroxisome proliferatoractivated receptor Î³ agonists. Lancet Oncology, The, 2004, 5, 419-429. | 10.7 | 413 |
| 16 | Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6058-6063. | 7.1 | 408 |
| 17 | <scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in earlyâ€stage Alzheimer's disease and associate with neuronal injury markers. EMBO Molecular Medicine, 2016, 8, 466-476. | 6.9 | 392 |
| 18 | Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. Journal of Chemical Neuroanatomy, 2005, 30, 144-157. | 2.1 | 387 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Neuroinflammatory processes in Alzheimerâ€™s disease. Journal of Neural Transmission, 2010, 117, 919-947. | 2.8 | 380 |
| 20 | Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. International Journal of Developmental Neuroscience, 2006, 24, 167-176. | 1.6 | 375 |
| 21 | Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimer's Research and Therapy, 2020, 12, 69. | 6.2 | 367 |
| 22 | Nonsteroidal anti-inflammatory drugs repress Î²-secretase gene promoter activity by the activation of PPARÎ³. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 443-448. | 7.1 | 365 |
| 23 | Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimerâ€™s Disease: a Comparative Overview. Molecular Neurobiology, 2014, 50, 534-544. | 4.0 | 349 |
| 24 | Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IÎºBÎ± induction and block of NFÎºB and iNOS activation. Journal of Neurochemistry, 2004, 88, 494-501. | 3.9 | 347 |
| 25 | Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-Î³ Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of Î²-Secretase. Journal of Neuroscience, 2003, 23, 9796-9804. | 3.6 | 347 |
| 26 | TLR2 Is a Primary Receptor for Alzheimerâ€™s Amyloid Î² Peptide To Trigger Neuroinflammatory Activation. Journal of Immunology, 2012, 188, 1098-1107. | 0.8 | 346 |
| 27 | Persistent cognitive impairment, hippocampal atrophy and EEG changes in sepsis survivors. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 62-69. | 1.9 | 341 |
| 28 | Î-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature, 2015, 526, 443-447. | 27.8 | 308 |
| 29 | Distinct and Non-Redundant Roles of Microglia and Myeloid Subsets in Mouse Models of Alzheimer's Disease. Journal of Neuroscience, 2011, 31, 11159-11171. | 3.6 | 286 |
| 30 | PPARÎ³/RXRÎ±-Induced and CD36-Mediated Microglial Amyloid-Î² Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice. Journal of Neuroscience, 2012, 32, 17321-17331. | 3.6 | 277 |
| 31 | Long-term cerebral consequences of sepsis. Lancet Neurology, The, 2014, 13, 630-636. | 10.2 | 273 |
| 32 | Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Science Translational Medicine, 2016, 8, 333ra50. | 12.4 | 271 |
| 33 | Locus Ceruleus Degeneration Promotes Alzheimer Pathogenesis in Amyloid Precursor Protein 23 Transgenic Mice. Journal of Neuroscience, 2006, 26, 1343-1354. | 3.6 | 268 |
| 34 | Nitration of Tyrosine 10 Critically Enhances Amyloid Î² Aggregation and Plaque Formation. Neuron, 2011, 71, 833-844. | 8.1 | 259 |
| 35 | Peroxisome Proliferator-Activated Receptor-Î³ Ligands Reduce Neuronal Inducible Nitric Oxide Synthase Expression and Cell DeathIn Vivo. Journal of Neuroscience, 2000, 20, 6862-6867. | 3.6 | 255 |
| 36 | PPARÎ³ Agonists as Therapeutics for the Treatment of Alzheimer's Disease. Neurotherapeutics, 2008, 5, 481-489. | 4.4 | 254 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Neuroglia in neurodegeneration. Brain Research Reviews, 2010, 63, 189-211. | 9.0 | 247 |
| 38 | A Panâ€<scp>E</scp>uropean Study of theC9orf72Repeat Associated with<scp>FTLD</scp>: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373. | 2.5 | 247 |
| 39 | Truncated and modified amyloid-beta species. Alzheimer's Research and Therapy, 2014, 6, 28. | 6.2 | 233 |
| 40 | Noradrenergic Depletion Potentiates Î²-Amyloid-Induced Cortical Inflammation: Implications for Alzheimer's Disease. Journal of Neuroscience, 2002, 22, 2434-2442. | 3.6 | 231 |
| 41 | The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer's disease. Immunology and Cell Biology, 2020, 98, 28-41. | 2.3 | 231 |
| 42 | Systemic inflammation impairs microglial AÎ² clearance through <scp>NLRP</scp> 3 inflammasome. EMBO Journal, 2019, 38, e101064. | 7.8 | 226 |
| 43 | Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism. Journal of Neuroinflammation, 2008, 5, 38. | 7.2 | 223 |
| 44 | Innate Immunity and Neurodegeneration. Annual Review of Medicine, 2018, 69, 437-449. | 12.2 | 221 |
| 45 | Expression and function of inducible nitric oxide synthase in neurons. Journal of Neuroimmunology, 2001, 114, 8-18. | 2.3 | 214 |
| 46 | Long-term cognitive impairment, neuronal loss and reduced cortical cholinergic innervation after recovery from sepsis in a rodent model. Experimental Neurology, 2007, 204, 733-740. | 4.1 | 206 |
| 47 | Noradrenergic regulation of inflammatory gene expression in brain. Neurochemistry International, 2002, 41, 357-365. | 3.8 | 199 |
| 48 | The Oral Antidiabetic Pioglitazone Protects from Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic Mice. Journal of Neuroscience, 2005, 25, 7805-7812. | 3.6 | 196 |
| 49 | Induction of Nitric Oxide Synthase and Nitric Oxideâ€Mediated Apoptosis in Neuronal PC12 Cells After Stimulation with Tumor Necrosis FActorâ€Î±/Lipopolysaccharide. Journal of Neurochemistry, 1998, 71, 88-94. | 3.9 | 186 |
| 50 | Targeting Neuroinflammation to Treat Alzheimerâ€™s Disease. CNS Drugs, 2017, 31, 1057-1082. | 5.9 | 182 |
| 51 | Statins Promote the Degradation of Extracellular Amyloid Î²-Peptide by Microglia via Stimulation of Exosome-associated Insulin-degrading Enzyme (IDE) Secretion. Journal of Biological Chemistry, 2010, 285, 37405-37414. | 3.4 | 176 |
| 52 | Peripheral and central immune system crosstalk in Alzheimer disease â€" a research prospectus. Nature Reviews Neurology, 2021, 17, 689-701. | 10.1 | 169 |
| 53 | Noradrenaline deficiency in brain increases Î²-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiology of Aging, 2007, 28, 1206-1214. | 3.1 | 168 |
| 54 | Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiology of Aging, 2001, 22, 937-944. | 3.1 | 167 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Critical Role of Astroglial Apolipoprotein E and Liver X Receptor-Î± Expression for Microglial AÎ² Phagocytosis. Journal of Neuroscience, 2011, 31, 7049-7059. | 3.6 | 163 |
| 56 | Extracellular phosphorylation of the amyloid Î²-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. EMBO Journal, 2011, 30, 2255-2265. | 7.8 | 160 |
| 57 | Microglial activation in a neuroinflammational animal model of schizophrenia â€" a pilot study. Schizophrenia Research, 2011, 131, 96-100. | 2.0 | 158 |
| 58 | Danger-associated molecular patterns in Alzheimerâ€™s disease. Journal of Leukocyte Biology, 2017, 101, 87-98. | 3.3 | 158 |
| 59 | Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. Cell, 2021, 184, 5089-5106.e21. | 28.9 | 158 |
| 60 | The Role of Peroxisome Proliferator-Activated Receptor-Î³ (PPARÎ³) in Alzheimerâ€™s Disease. CNS Drugs, 2008, 22, 1-14. | 5.9 | 155 |
| 61 | Effect of pioglitazone medication on the incidence of dementia. Annals of Neurology, 2015, 78, 284-294. | 5.3 | 153 |
| 62 | Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. Journal of Neuroimmunology, 1999, 100, 156-168. | 2.3 | 146 |
| 63 | Neuronal and Glial Coexpression of Argininosuccinate Synthetase and Inducible Nitric Oxide Synthase in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2001, 60, 906-916. | 1.7 | 134 |
| 64 | Noradrenergic depletion increases inflammatory responses in brain: effects on IÎºB and HSP70 expression. Journal of Neurochemistry, 2003, 85, 387-398. | 3.9 | 134 |
| 65 | Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimerâ€™s disease (DELCODE). Alzheimer's Research and Therapy, 2018, 10, 15. | 6.2 | 131 |
| 66 | Gray matter atrophy pattern in elderly with subjective memory impairment. Alzheimer's and Dementia, 2014, 10, 99-108. | 0.8 | 129 |
| 67 | NOS2Gene Deficiency Protects from Sepsis-Induced Long-Term Cognitive Deficits. Journal of Neuroscience, 2009, 29, 14177-14184. | 3.6 | 125 |
| 68 | A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e37885. | 2.5 | 125 |
| 69 | Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 21. | 6.2 | 124 |
| 70 | Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARÎ³. Journal of Neurochemistry, 2002, 81, 1052-1060. | 3.9 | 119 |
| 71 | Inflammasome activation and innate immunity in <scp>A</scp>lzheimer's disease. Brain Pathology, 2017, 27, 220-222. | 4.1 | 119 |
| 72 | Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochemistry International, 2010, 57, 375-382. | 3.8 | 116 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Inhibition of Glycosphingolipid Biosynthesis Reduces Secretion of the Î²-Amyloid Precursor Protein and Amyloid Î²-Peptide*[boxs]. Journal of Biological Chemistry, 2005, 280, 28110-28117. | 3.4 | 115 |
| 74 | Neuroimmune Connections in Aging and Neurodegenerative Diseases. Trends in Immunology, 2020, 41, 300-312. | 6.8 | 111 |
| 75 | Î²-Amyloid Clustering around ASC Fibrils Boosts Its Toxicity in Microglia. Cell Reports, 2020, 30, 3743-3754.e6. | 6.4 | 109 |
| 76 | CXCR3 promotes plaque formation and behavioral deficits in an Alzheimerâ€™s disease model. Journal of Clinical Investigation, 2015, 125, 365-378. | 8.2 | 106 |
| 77 | Common variants in the HLA-DQ region confer susceptibility to idiopathic achalasia. Nature Genetics, 2014, 46, 901-904. | 21.4 | 104 |
| 78 | Proinflammatory Stimulation and Pioglitazone Treatment Regulate Peroxisome Proliferator-Activated Receptor Î³ Levels in Peripheral Blood Mononuclear Cells from Healthy Controls and Multiple Sclerosis Patients. Journal of Immunology, 2005, 175, 4948-4955. | 0.8 | 103 |
| 79 | Activation of the <scp>NLRP</scp>3 inflammasome in microglia: the role of ceramide. Journal of Neurochemistry, 2017, 143, 534-550. | 3.9 | 101 |
| 80 | Impact and Therapeutic Potential of PPARs in Alzheimers Disease. Current Neuropharmacology, 2011, 9, 643-650. | 2.9 | 99 |
| 81 | Inhibition of in Vivo Glioma Growth and Invasion by Peroxisome Proliferator-Activated Receptor Î³ Agonist Treatment. Molecular Pharmacology, 2006, 70, 1524-1533. | 2.3 | 98 |
| 82 | PPARÎ³ as a therapeutic target in central nervous system diseases. Neurochemistry International, 2006, 49, 136-144. | 3.8 | 97 |
| 83 | Do infections have a role in the pathogenesis of Alzheimer disease?. Nature Reviews Neurology, 2020, 16, 193-197. | 10.1 | 96 |
| 84 | Selective Loss of Noradrenaline Exacerbates Early Cognitive Dysfunction and Synaptic Deficits in APP/PS1 Mice. Biological Psychiatry, 2013, 73, 454-463. | 1.3 | 95 |
| 85 | Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Cell Death and Differentiation, 1998, 5, 847-857. | 11.2 | 93 |
| 86 | Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410. | 7.7 | 93 |
| 87 | Soluble AÎ² oligomers and protofibrils induce NLRP3 inflammasome activation in microglia. Journal of Neurochemistry, 2020, 155, 650-661. | 3.9 | 91 |
| 88 | Disease-Modifying Therapies in Alzheimer???s Disease. Drugs, 2006, 66, 2075-2093. | 10.9 | 90 |
| 89 | TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309. | 2.5 | 87 |
| 90 | Drug Insight: effects mediated by peroxisome proliferator-activated receptor-Î³ in CNS disorders. Nature Clinical Practice Neurology, 2007, 3, 496-504. | 2.5 | 86 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Anti-inflammatory and antiproliferative actions of PPAR-Î³ agonists on T lymphocytes derived from MS patients. Journal of Leukocyte Biology, 2004, 75, 478-485. | 3.3 | 85 |
| 92 | Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimerâ€™s disease. Brain, 2018, 141, 1186-1200. | 7.6 | 83 |
| 93 | GGA1 Is Expressed in the Human Brain and Affects the Generation of Amyloid Â-Peptide. Journal of Neuroscience, 2006, 26, 12838-12846. | 3.6 | 82 |
| 94 | Reduction of Amyloid Angiopathy and AÎ² Plaque Burden after Enriched Housing in TgCRND8 Mice. American Journal of Pathology, 2006, 169, 544-552. | 3.8 | 81 |
| 95 | ADO: A disease ontology representing the domain knowledge specific to Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 238-246. | 0.8 | 77 |
| 96 | Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 25. | 6.2 | 74 |
| 97 | Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimerâ€™s Disease. Frontiers in Molecular Neuroscience, 2018, 11, 235. | 2.9 | 72 |
| 98 | Microglia in Alzheimer's Disease: The Good, the Bad and the Ugly. Current Alzheimer Research, 2016, 13, 370-380. | 1.4 | 72 |
| 99 | Early Changes in Hippocampal Neurogenesis in Transgenic Mouse Models for Alzheimerâ€™s Disease. Molecular Neurobiology, 2016, 53, 5796-5806. | 4.0 | 71 |
| 100 | Norepinephrine Increases IºBÎ± Expression in Astrocytes. Journal of Biological Chemistry, 2002, 277, 29662-29668. | 3.4 | 70 |
| 101 | The Heat Shock Response Inhibits NF-ÎºB Activation, Nitric Oxide Synthase Type 2 Expression, and Macrophage/Microglial Activation in Brain. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 800-811. | 4.3 | 67 |
| 102 | Cortical Thinning in Individuals with Subjective Memory Impairment. Journal of Alzheimer's Disease, 2015, 45, 139-146. | 2.6 | 66 |
| 103 | Microglia modulation through external vagus nerve stimulation in a murine model of Alzheimer's disease. Journal of Neurochemistry, 2018, 146, 76-85. | 3.9 | 65 |
| 104 | Intrinsic regulation of brain inflammatory responses. Cellular and Molecular Neurobiology, 2003, 23, 625-635. | 3.3 | 64 |
| 105 | Higher CSF Tau Levels Are Related to Hippocampal Hyperactivity and Object Mnemonic Discrimination in Older Adults. Journal of Neuroscience, 2019, 39, 8788-8797. | 3.6 | 64 |
| 106 | Imaging-Guided Gene Therapy of Experimental Gliomas. Cancer Research, 2007, 67, 1706-1715. | 0.9 | 62 |
| 107 | Loss of Î³-Secretase Function Impairs Endocytosis of Lipoprotein Particles and Membrane Cholesterol Homeostasis. Journal of Neuroscience, 2008, 28, 12097-12106. | 3.6 | 62 |
| 108 | The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 614-628. | 7.9 | 61 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Mrp14 Deficiency Ameliorates Amyloid Î² Burden by Increasing Microglial Phagocytosis and Modulation of Amyloid Precursor Protein Processing. Journal of Neuroscience, 2012, 32, 17824-17829. | 3.6 | 60 |
| 110 | CNS-Targeted Production of IL-17A Induces Glial Activation, Microvascular Pathology and Enhances the Neuroinflammatory Response to Systemic Endotoxemia. PLoS ONE, 2013, 8, e57307. | 2.5 | 60 |
| 111 | PLD3 in non-familial Alzheimer's disease. Nature, 2015, 520, E3-E5. | 27.8 | 58 |
| 112 | Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology, 2020, 95, e1134-e1143. | 1.1 | 58 |
| 113 | Î±â€secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits AÎ² generation. Journal of Neurochemistry, 2009, 111, 1369-1382. | 3.9 | 57 |
| 114 | Selective Potentiation of Drug Cytotoxicity by NSAID in Human Glioma Cells: The Role of COX-1 and MRP. Biochemical and Biophysical Research Communications, 1999, 259, 600-605. | 2.1 | 55 |
| 115 | PPARÎ³ and RXRÎ³ ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models. Journal of Neurochemistry, 2009, 109, 1779-1790. | 3.9 | 55 |
| 116 | Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0132227. | 2.5 | 55 |
| 117 | Inflammasomeâ€mediated innate immunity in Alzheimer's disease. FASEB Journal, 2019, 33, 13075-13084. | 0.5 | 55 |
| 118 | Cerebral dysfunctions caused by sepsis during ageing. Nature Reviews Immunology, 2022, 22, 444-458. | 22.7 | 55 |
| 119 | Ear2 Deletion Causes Early Memory and Learning Deficits in APP/PS1 Mice. Journal of Neuroscience, 2014, 34, 8845-8854. | 3.6 | 54 |
| 120 | Role for peroxisome proliferator-activated receptor-? in Alzheimer's disease. Annals of Neurology, 2001, 49, 276-276. | 5.3 | 53 |
| 121 | The AD-CSF-Index Discriminates Alzheimer's Disease Patients from Healthy Controls: A Validation Study. Journal of Alzheimer's Disease, 2013, 36, 67-77. | 2.6 | 53 |
| 122 | Microglial NLRP3 Inflammasome Activation upon TLR2 and TLR5 Ligation by Distinct Î±-Synuclein Assemblies. Journal of Immunology, 2021, 207, 2143-2154. | 0.8 | 53 |
| 123 | Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2013, 34, 351-354. | 3.1 | 52 |
| 124 | Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2018, 17, 681-688. | 10.2 | 51 |
| 125 | Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimerâ€™s disease pathogenesis. Nature Neuroscience, 2019, 22, 1258-1268. | 14.8 | 48 |
| 126 | Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARÎ³) in murine primary astrocytes and neurons. Journal of Neurochemistry, 2003, 86, 907-916. | 3.9 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Long-term neuromuscular sequelae of critical illness. Journal of Neurology, 2013, 260, 151-157. | 3.6 | 45 |
| 128 | SUCLG2 identified as both a determinator of CSF AÎ²1â€“42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human Molecular Genetics, 2014, 23, 6644-6658. | 2.9 | 45 |
| 129 | Suppressive effects of ansamycins on inducible nitric oxide synthase expression and the development of experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 2002, 67, 461-470. | 2.9 | 44 |
| 130 | IL-17A Promotes Granulocyte Infiltration, Myelin Loss, Microglia Activation, and Behavioral Deficits During Cuprizone-Induced Demyelination. Molecular Neurobiology, 2018, 55, 946-957. | 4.0 | 44 |
| 131 | Clinical Symptoms and Risk Factors in Cerebral Microangiopathy Patients. PLoS ONE, 2013, 8, e53455. | 2.5 | 44 |
| 132 | Î²-Amyloid Peptides Decrease Soluble Guanylyl Cyclase Expression in Astroglial Cells. Neurobiology of Disease, 2002, 10, 139-149. | 4.4 | 43 |
| 133 | A novel CHCHD10 mutation implicates a Mia40â€dependent mitochondrial import deficit in ALS. EMBO Molecular Medicine, 2018, 10, . | 6.9 | 43 |
| 134 | mTOR-dependent translation amplifies microglia priming in aging mice. Journal of Clinical Investigation, 2021, 131, . | 8.2 | 43 |
| 135 | A distinct clinical phenotype in a German kindred with motor neuron disease carrying aCHCHD10mutation. Brain, 2015, 138, e376-e376. | 7.6 | 42 |
| 136 | Proteopathic tau primes and activates interleukin-1Î² via myeloid-cell-specific MyD88- and NLRP3-ASC-inflammasome pathway. Cell Reports, 2021, 36, 109720. | 6.4 | 42 |
| 137 | Neuroinflammatory and behavioural changes in the Atp7B mutant mouse model of Wilsonâ€™s disease. Journal of Neurochemistry, 2011, 118, 105-112. | 3.9 | 41 |
| 138 | Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer-prone mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9002-9007. | 7.1 | 41 |
| 139 | Microglia take centre stage in neurodegenerative disease. Nature Reviews Immunology, 2019, 19, 79-80. | 22.7 | 41 |
| 140 | Microglial PDâ€1 stimulation by astrocytic PDâ€L1 suppresses neuroinflammation and Alzheimerâ€™s disease pathology. EMBO Journal, 2021, 40, e108662. | 7.8 | 41 |
| 141 | PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica, 2020, 139, 1025-1044. | 7.7 | 40 |
| 142 | In vivo characterization of functional states of cortical microglia during peripheral inflammation. Brain, Behavior, and Immunity, 2020, 87, 243-255. | 4.1 | 38 |
| 143 | Doublecortin expression in CD8+ Tâ€cells and microglia at sites of amyloidâ€Î² plaques: A potential role in shaping plaque pathology?. Alzheimer's and Dementia, 2018, 14, 1022-1037. | 0.8 | 36 |
| 144 | Enduring Changes in Neuronal Function upon Systemic Inflammation Are NLRP3 Inflammasome Dependent. Journal of Neuroscience, 2020, 40, 5480-5494. | 3.6 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Pan-PPAR Modulation Effectively Protects APP/PS1 Mice from Amyloid Deposition and Cognitive Deficits. Molecular Neurobiology, 2015, 51, 661-671. | 4.0 | 35 |
| 146 | Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. Alzheimer's and Dementia, 2020, 16, 1504-1514. | 0.8 | 35 |
| 147 | Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. Synapse, 1997, 26, 381-391. | 1.2 | 34 |
| 148 | Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. Neurobiology of Aging, 2014, 35, 2657.e13-2657.e19. | 3.1 | 34 |
| 149 | Transcriptome analysis of alcohol-treated microglia reveals downregulation of beta amyloid phagocytosis. Journal of Neuroinflammation, 2018, 15, 141. | 7.2 | 34 |
| 150 | The ERICA Score: An MR Imagingâ€“based Visual Scoring System for the Assessment of Entorhinal Cortex Atrophy in Alzheimer Disease. Radiology, 2018, 288, 226-333. | 7.3 | 33 |
| 151 | The heat shock response reduces myelin oligodendrocyte glycoproteinâ€induced experimental autoimmune encephalomyelitis in mice. Journal of Neurochemistry, 2001, 77, 568-579. | 3.9 | 32 |
| 152 | Dysregulation of TLR5 and TAM Ligands in the Alzheimerâ€™s Brain as Contributors to Disease Progression. Molecular Neurobiology, 2019, 56, 6539-6550. | 4.0 | 31 |
| 153 | Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-Î² dexamethasone, and p53 gene transfer. Oncogene, 1998, 17, 2323-2332. | 5.9 | 30 |
| 154 | Quantitative proteomics of synaptosome Sâ€nitrosylation in Alzheimerâ€™s disease. Journal of Neurochemistry, 2020, 152, 710-726. | 3.9 | 30 |
| 155 | Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. Alzheimer's and Dementia, 2020, 16, 292-304. | 0.8 | 29 |
| 156 | A microRNA signature that correlates with cognition and is a target against cognitive decline. EMBO Molecular Medicine, 2021, 13, e13659. | 6.9 | 29 |
| 157 | Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. Alzheimer's Research and Therapy, 2019, 11, 74. | 6.2 | 28 |
| 158 | Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's diseaseâ€”Data from three memory clinic studies. Alzheimer's and Dementia, 2019, 15, 185-193. | 0.8 | 28 |
| 159 | Induction of Argininosuccinate Synthetase in Rat Brain Glial Cells after Striatal Microinjection of Immunostimulants. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 898-907. | 4.3 | 27 |
| 160 | Temporal, regional, and cell-specific changes of iNOS expression after intrastriatal microinjection of interferon gamma and bacterial lipopolysaccharide. Journal of Chemical Neuroanatomy, 2000, 18, 167-179. | 2.1 | 27 |
| 161 | The Nonthiazolidinedione Tyrosine-Based Peroxisome Proliferator-Activated Receptor Î³ Ligand GW7845 Induces Apoptosis and Limits Migration and Invasion of Rat and Human Glioma Cells. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 806-813. | 2.5 | 27 |
| 162 | SFRP1 modulates astrocyteâ€toâ€microglia crosstalk in acute and chronic neuroinflammation. EMBO Reports, 2021, 22, e51696. | 4.5 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimerâ€™s disease. Neuron, 2022, 110, 1009-1022.e4. | 8.1 | 27 |
| 164 | Cannabinoid 1 Receptor Signaling on Hippocampal GABAergic Neurons Influences Microglial Activity. Frontiers in Molecular Neuroscience, 2018, 11, 295. | 2.9 | 26 |
| 165 | Systemic inflammation induced the delayed reduction of excitatory synapses in the CA3 during ageing. Journal of Neurochemistry, 2021, 159, 525-542. | 3.9 | 25 |
| 166 | Switching on the Lights for Gene Therapy. PLoS ONE, 2007, 2, e528. | 2.5 | 24 |
| 167 | Nitric Oxide Decreases the Enzymatic Activity of Insulin Degrading Enzyme in APP/PS1 Mice. Journal of NeuroImmune Pharmacology, 2012, 7, 165-172. | 4.1 | 24 |
| 168 | Interleukin-1Î² and lipopolysaccharide decrease soluble guanylyl cyclase in brain cells: NO-independent destabilization of protein and NO-dependent decrease of mRNA. Journal of Neuroimmunology, 2003, 144, 80-90. | 2.3 | 23 |
| 169 | Inflammation in Alzheimerâ€™s disease. Clinical Neuroscience Research, 2006, 6, 247-260. | 0.8 | 23 |
| 170 | Translocator protein and new targets for neuroinflammation. Clinical and Translational Imaging, 2015, 3, 391-402. | 2.1 | 23 |
| 171 | Prevalence of abnormal Alzheimerâ€™s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. Alzheimer's Research and Therapy, 2019, 11, 8. | 6.2 | 23 |
| 172 | Inflammasome activation in neurodegenerative diseases. Essays in Biochemistry, 2021, 65, 885-904. | 4.7 | 23 |
| 173 | The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta (AÎ²) species on long-term potentiation (LTP). Neuropharmacology, 2018, 140, 184-192. | 4.1 | 22 |
| 174 | Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845. | 0.8 | 22 |
| 175 | An immune-cell signature marks the brain in Alzheimerâ€™s disease. Nature, 2020, 577, 322-323. | 27.8 | 21 |
| 176 | Multicenter Resting State Functional Connectivity in Prodromal and Dementia Stages of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, 801-813. | 2.6 | 19 |
| 177 | Multiâ€cohort profiling reveals elevated CSF levels of brainâ€enriched proteins in Alzheimerâ€™s disease. Annals of Clinical and Translational Neurology, 2021, 8, 1456-1470. | 3.7 | 19 |
| 178 | Variability and temporal dynamics of novel object recognition in aging male C57BL/6 mice. Behavioural Processes, 2018, 157, 711-716. | 1.1 | 17 |
| 179 | CNS-Specific Synthesis of Interleukin 23 Induces a Progressive Cerebellar Ataxia and the Accumulation of Both T and B Cells in the Brain: Characterization of a Novel Transgenic Mouse Model. Molecular Neurobiology, 2019, 56, 7977-7993. | 4.0 | 17 |
| 180 | Multimodal MRI analysis of basal forebrain structure and function across the Alzheimerâ€™s disease spectrum. NeuroImage: Clinical, 2020, 28, 102495. | 2.7 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Restraint stress increases neuroinflammation independently of amyloid Î² levels in amyloid precursor protein/PS1 transgenic mice. Journal of Neurochemistry, 2011, 116, 43-52. | 3.9 | 16 |
| 182 | Long-term exposure to fine particulate matter, lung function and cognitive performance: A prospective Dutch cohort study on the underlying routes. Environmental Research, 2021, 201, 111533. | 7.5 | 16 |
| 183 | Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimerâ€™s Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness. Journal of Alzheimer's Disease, 2019, 72, 455-465. | 2.6 | 15 |
| 184 | Interrelations of AlzheimerÂ´s disease candidate biomarkers neurogranin, fatty acidâ€binding protein 3 and ferritin to neurodegeneration and neuroinflammation. Journal of Neurochemistry, 2021, 157, 2210-2224. | 3.9 | 15 |
| 185 | Hippocampal and Hippocampal-Subfield Volumes From Early-Onset Major Depression and Bipolar Disorder to Cognitive Decline. Frontiers in Aging Neuroscience, 2021, 13, 626974. | 3.4 | 15 |
| 186 | Intramembranous processing by Î³â€secretase regulates reverse signaling of ephrinâ€B2 in migration of microglia. Glia, 2017, 65, 1103-1118. | 4.9 | 13 |
| 187 | In vivo mechanisms of cortical network dysfunction induced by systemic inflammation. Brain, Behavior, and Immunity, 2021, 96, 113-126. | 4.1 | 12 |
| 188 | Time course of dementia following sepsis in German health claims data. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, . | 6.0 | 12 |
| 189 | TREM2 modulates differential deposition of modified and non-modified AÎ² species in extracellular plaques and intraneuronal deposits. Acta Neuropathologica Communications, 2021, 9, 168. | 5.2 | 12 |
| 190 | Opposing Roles for CXCR3 Signaling in Central Nervous System Versus Ocular Inflammation Mediated by the Astrocyte-Targeted Production of IL-12. American Journal of Pathology, 2011, 179, 2346-2359. | 3.8 | 10 |
| 191 | The Entorhinal Cortex Atrophy Score Is Diagnostic and Prognostic in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 75, 99-108. | 2.6 | 10 |
| 192 | T cells in Alzheimer's disease: space invaders. Lancet Neurology, The, 2020, 19, 285-287. | 10.2 | 10 |
| 193 | Teaching an old dog new tricks: serum troponin T as a biomarker in amyotrophic lateral sclerosis. Brain Communications, 2021, 3, fcab274. | 3.3 | 10 |
| 194 | Sepsis-associated encephalopathy versus sepsis-induced encephalopathyâ€“Authors' reply. Lancet Neurology, The, 2014, 13, 968-969. | 10.2 | 9 |
| 195 | Reduction of microbleeds by immunosuppression in a patient with AÎ²-related vascular inflammation. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e165. | 6.0 | 9 |
| 196 | Microglia in Alzheimerâ€™s disease: Local heroes!. Journal of Experimental Medicine, 2020, 217, . | 8.5 | 9 |
| 197 | Major Surgery Affects Memory in Individuals with Cerebral Amyloid-Î² Pathology. Journal of Alzheimer's Disease, 2021, 79, 863-874. | 2.6 | 9 |
| 198 | Differential interaction with <scp>TREM2</scp> modulates microglial uptake of modified AÎ² species. Glia, 2021, 69, 2917-2932. | 4.9 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | P3â€591: A GERMAN VERSION OF THE LIFETIME OF EXPERIENCES QUESTIONNAIRE (LEQ) TO MEASURE COGNITIVE RESERVE: VALIDATION RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1352. | 0.8 | 8 |
| 200 | Longitudinal Neurocognitive and Pulmonological Profile of Long COVID-19: Protocol for the COVIMMUNE-Clin Study. JMIR Research Protocols, 2021, 10, e30259. | 1.0 | 8 |
| 201 | The other brain. Journal of Clinical Investigation, 2010, 120, 1789-1789. | 8.2 | 7 |
| 202 | Norepinephrine as a modulator of microglial dynamics. Nature Neuroscience, 2019, 22, 1745-1746. | 14.8 | 7 |
| 203 | Microglia: Youâ€™ll Never Walk Alone!. Immunity, 2018, 48, 195-197. | 14.3 | 6 |
| 204 | p38 Inhibition Decreases Tau Toxicity in Microglia and Improves Their Phagocytic Function. Molecular Neurobiology, 2022, 59, 1632-1648. | 4.0 | 6 |
| 205 | Thoughts on Obesity and Brain Glucose. Cell, 2016, 165, 773-775. | 28.9 | 5 |
| 206 | Proteome profiling of s-nitrosylated synaptosomal proteins by isobaric mass tags. Journal of Neuroscience Methods, 2017, 291, 95-100. | 2.5 | 5 |
| 207 | A rare heterozygous TREM2 coding variant identified in familial clustering of dementia affects an intrinsically disordered protein region and function of TREM2. Human Mutation, 2020, 41, 169-181. | 2.5 | 4 |
| 208 | Vaccination with (1â€“11)E2 in alum efficiently induces an antibody response to Î²-amyloid without affecting brain Î²-amyloid load and microglia activation in 3xTg mice. Aging Clinical and Experimental Research, 2021, 33, 1383-1387. | 2.9 | 3 |
| 209 | IFN-Î²1a (RebifÂ®) Modifies the Expression of Microfilament-Associated Cell-Cell Contacts in C6 Glioma Cells. Journal of Interferon and Cytokine Research, 2003, 23, 83-89. | 1.2 | 2 |
| 210 | [P2â€“088]: CHRONIC AND ACUTE SYSTEMIC INFLAMMATION AND LONGâ€TERM COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P640. | 0.8 | 2 |
| 211 | Deletion of the inflammatory S100-A9/MRP14 protein does not influence survival in hSOD1G93A ALS mice. Neurobiology of Aging, 2021, 101, 181-186. | 3.1 | 2 |
| 212 | Falls at advanced age â€“ The importance to search for benign paroxysmal positional vertigo (BPPV). Experimental Gerontology, 2022, 165, 111868. | 2.8 | 2 |
| 213 | Noradrenergic denervation facilitates the release of acetylcholine and serotonin in the hippocampus: Towards a mechanism underlying upregulations described in MCI patients. Experimental Neurology, 2009, 217, 237-239. | 4.1 | 1 |
| 214 | IL-17A promotes myelin loss and inflammatory response during Cuprizone-induced demyelination. Journal of Neuroimmunology, 2014, 275, 110. | 2.3 | 1 |
| 215 | United Again: STING and the Police. Neuron, 2017, 96, 1207-1208. | 8.1 | 1 |
| 216 | P4â€068: LEVELS OF THE ASTROCYTEâ€DERIVED PROTEINS GFAP AND S100B IN THE CEREBROSPINAL FLUID OF HEALTHY INDIVIDUALS AND ALZHEIMER'S DISEASE PATIENTS AT DIFFERENT DISEASE STAGES. Alzheimer's and Dementia, 2018, 14, P1458. | 0.8 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Feasibility of mobile appâ€based assessment of memory functions: Insights from a citizen science study. Alzheimer's and Dementia, 2020, 16, e039149. | 0.8 | 1 |
| 218 | Decreased cortical thickness in individuals with subjective cognitive decline with and without CSFâ€ADâ€pathology: Data from the DELCODE Study. Alzheimer's and Dementia, 2020, 16, e044741. | 0.8 | 1 |
| 219 | [P2â€“074]: MODELING OF HIDDEN CAUSES FOR DYNAMIC CHANGES IN STRUCTURAL INTEGRITY AND COGNITION IN SUBJECTIVE COGNITIVE DECLINE: A DELCODE PROJECT. Alzheimer's and Dementia, 2017, 13, P634. | 0.8 | 0 |
| 220 | [P3â€“164]: FUNCTIONAL CHARACTERIZATION OF A RARE GENETIC VARIANT IN PHOSPHOLIPASE CÎ³2 WHICH IS ASSOCIATED WITH A BENEFICIAL EFFECT ON THE PROGRESSION OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P997. | 0.8 | 0 |
| 221 | P1â€379: CORTICAL THINNING IN SUBJECTIVE COGNITIVE DECLINE WITH AND WITHOUT AD PATHOLOGY: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P443. | 0.8 | 0 |
| 222 | P3â€327: NEUROPSYCHIATRIC SYMPTOMS IN ATâ€RISK GROUPS FOR AD DEMENTIA AND THEIR RELATION TO AD BIOMARKERS: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1206. | 0.8 | 0 |
| 223 | P2â€434: EFFECTS OF AGE AND CSF MEASURES OF TAU ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. Alzheimer's and Dementia, 2018, 14, P879. | 0.8 | 0 |
| 224 | ICâ€Pâ€084: EFFECTS OF AGE AND CSF MEASURES OF TAU ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. Alzheimer's and Dementia, 2018, 14, P72. | 0.8 | 0 |
| 225 | P1â€028: OCCUPATIONAL COGNITIVE REQUIREMENTS ARE AN IMPORTANT PROXY MEASURE OF COGNITIVE RESERVE: EVIDENCE FROM THE AGECODE AND DELCODE STUDIES. Alzheimer's and Dementia, 2018, 14, P276. | 0.8 | 0 |
| 226 | P3â€366: MULTICENTER RESTING STATE FUNCTIONAL CONNECTIVITY IN PRODROMAL AND DEMENTIA STAGES OF ALZHEIMER'S DISEASE: RESULTS FROM THE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1228. | 0.8 | 0 |
| 227 | F4â€07â€03: RELATIONSHIP BETWEEN LOCUS COERULEUS MRI CONTRAST, COGNITION AND CSF BIOMARKERS IN AGING AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1393. | 0.8 | 0 |
| 228 | F1â€04â€02: ASSOCIATION BETWEEN NEURAL NOVELTY RESPONSES AND CSF BIOMARKERS OF ALZHEIMER'S DISEASE: ANATOMICAL SPECIFICITY AND DEPENDENCE ON ATROPHY. Alzheimer's and Dementia, 2018, 14, P206. | 0.8 | 0 |
| 229 | F4â€08â€04: SUBJECTIVE COGNITIVE DECLINE, AS MEASURED WITH A STRUCTURED INTERVIEW, IS RELATED TO AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1396. | 0.8 | 0 |
| 230 | F1â€04â€03: EFFECTS OF AGE AND TAU MEASURED IN CSF ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. Alzheimer's and Dementia, 2018, 14, P207. | 0.8 | 0 |
| 231 | Innate immune activation of the NLRP3 inflammasome pathway drives tau pathology. Alzheimer's and Dementia, 2020, 16, e039815. | 0.8 | 0 |
| 232 | Cognitive and biological characteristics of stage 2 of AD in the clinical multicenter DELCODE Study. Alzheimer's and Dementia, 2020, 16, e040265. | 0.8 | 0 |
| 233 | NLRP3 inflammasome activation regulates microglial migration. Alzheimer's and Dementia, 2020, 16, e040946. | 0.8 | 0 |
| 234 | Hippocampal volumetric variability is associated with memory in subjective cognitive decline. Alzheimer's and Dementia, 2020, 16, e043527. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Overview of immune system in AD. Alzheimer's and Dementia, 2020, 16, e044146. | 0.8 | 0 |
| 236 | Awareness of cognitive decline and CSFâ€biomarkers in memory clinic patients: Results from the DELCODEâ€study. Alzheimer's and Dementia, 2020, 16, e044744. | 0.8 | 0 |
| 237 | The effects of Mediterranean diet on memory and Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2020, 16, e045349. | 0.8 | 0 |
| 238 | Characterization of the NIAâ€AA Research Framework stage 2 in the longitudinal multicenter DELCODE study. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |
| 239 | In vivo amyloid staging in individuals with subjective cognitive decline in DELCODE Study. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |
| 240 | Artificial neural network visualization methods reveal diagnostically relevant brain regions to detect Alzheimerâ€™s disease: The first step towards comprehensive artificial intelligence. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |
| 241 | Prediction of amyloidâ€positivity in individuals with subjective cognitive decline: Machine learning approaches to optimize numberâ€neededâ€toâ€screen. Alzheimer's and Dementia, 2021, 17, . | 0.8 | 0 |
| 242 | CA3 excitatory synapse loss as a chronic effect of septic shock in middle-aged mice.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e052228. | 0.8 | 0 |